Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 568 clinical trials
None
GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies

This trial is an open-label, safety trial of GEN3014 (HexaBody-CD38). The trial consists of two parts: a dose escalation part phase 1, first-in-human (FIH), and an expansion part phase 2a.

  • 0 views
  • 11 Sep, 2021
  • 9 locations
None
A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004)

The purpose of the study is to determine the safety and tolerability of pembrolizumab/vibostolimab (MK-7684A) in hematological malignancies. This study will also evaluate the overall response

kinase inhibitor
hepatitis b surface antigen
measurable disease
mantle cell lymphoma
lymphoma
  • 0 views
  • 21 Oct, 2021
None
Dose Escalation Study of Teclistamab a Humanized BCMA*CD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for Teclistamab and to characterize the safety and tolerability of Teclistamab at the RP2Ds.

estrogen
proteasome inhibitor
multiple myeloma
  • 292 views
  • 13 Oct, 2021
  • 16 locations
None
Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to characterize the safety of Talquetamab and to determine the recommended Phase 2 dose(s) (RP2Ds) and dosing schedule assessed to be safe for Talquetamab (Part 1 [Dose Escalation]) and to further characterize the safety of Talquetamab at the recommended Phase 2 dose(s) (RP2Ds) (Part …

human chorionic gonadotropin
measurable disease
multiple myeloma
  • 65 views
  • 15 Oct, 2021
  • 16 locations
None
Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

The investigators' purpose was to assess the feasibility of dosage individualization of the commonly used antineoplastic drugs and anti-infective drugs in children with hematoplastic disease.

antineoplastic
colony stimulating factor
bortezomib
imatinib
granulocyte colony stimulating factor
  • 6 views
  • 24 Jan, 2021
  • 1 location
None
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is evaluate the efficacy of teclistamab at the recommended Phase 2 dose (RP2D).

measurable disease
multiple myeloma
  • 0 views
  • 18 Oct, 2021
  • 74 locations
None
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the efficacy of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).

measurable disease
multiple myeloma
  • 0 views
  • 15 Oct, 2021
  • 80 locations
None
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small

kinase inhibitor
leukemia
hepatitis b surface antigen
measurable disease
mantle cell lymphoma
  • 2 views
  • 18 Oct, 2021
  • 15 locations
None
Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trials

This is a biology driven, monocentric study designed to identify actionable molecular alterations in cancer patients with advanced disease. In this trial, high throughput analysis will be carried out using next generation sequencing, and immunological profiling. Patients included in the BIP study and for whom a targetable genomic alteration had …

solid tumor
hematologic malignancy
cancer
metastatic malignant solid tumor
  • 16 views
  • 24 Jan, 2021
  • 5 locations
None
Durvalumab and Tremelimumab for Pediatric Malignancies

The purpose of the study is to determine the recommended dose of durvalumab and tremelimumab (immunotherapy drugs) in pediatric patients with advanced solid and hematological cancers and expand in a second phase to test the efficacy of these drugs once this dose is determined

durvalumab
leukemia
acute leukemia
cancer
lymphoma
  • 15 views
  • 29 Sep, 2021
  • 27 locations